Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape
NEW YORK, Jan. 22, 2025 /PRNewswire/ — Lindus Health, “the anti-CRO” running radically faster, more reliable clinical trials, announced today it has raised $55M in Series B funding. The round was led by new investor Balderton Capital, with support from Visionaries…